Logo

Finch Therapeutics Group, Inc.

FNCH

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that is in Phase 3 clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chron… read more

Healthcare

Biotechnology

4 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$14.00

Price

0.00%

$0.00

Market Cap

$22.481m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

+2558.9%

1y CAGR

+792.0%

3y CAGR

+629.0%

5y CAGR
Earnings

-$13.877m

+81.1%

1y CAGR

+6.2%

3y CAGR

-7.4%

5y CAGR
EPS

-$8.64

+81.1%

1y CAGR

+6.7%

3y CAGR

-7.6%

5y CAGR
Book Value

$9.079m

$49.750m

Assets

$40.671m

Liabilities

$27.791m

Debt
Debt to Assets

55.9%

-1.5x

Debt to EBITDA
Free Cash Flow

-$31.505m

+76.6%

1y CAGR

-20.3%

3y CAGR

-36.5%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases